• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Failure of treatment and protocol compliance in patients with acute lymphoblastic leukemia].

作者信息

Tang Jing-yan, Xue Hui-liang, Gu Long-jun, Chen Jing, Pan Ci, Chen Jing, Wang Yao-ping, Ye Hui, Dong Lu, Zou Jia-yin

机构信息

Department of Hematology/Oncology, Xinhua Hospital, Shanghai Children's Medical Center, Shanghai Second Medical University, Shanghai 200127, China.

出版信息

Zhonghua Er Ke Za Zhi. 2005 Jul;43(7):490-3.

PMID:16083545
Abstract

OBJECTIVE

To analyze the main reason of failure in treatment and compliance to protocol in children with acute lymphoblastic leukemia (ALL) at a single institute which is located at the most developed city of China.

METHODS

All the ALL patients who were diagnosed at the hospital from October 1998 to June 2003 were analyzed. The data were extracted from the department's tumor registry database. Failure in protocol compliance and treatment was analyzed within different risk groups, patients' resident area, and time period. The patients who had not received any therapy after ALL diagnosis were accounted as early protocol compliance failure, those who received therapy for less than 15 days were regarded as interim failure in protocol compliance, and those who gave up therapy or were lost in follow-up after 15 days with stable disease or complete remission (CR) were accounted as late compliance failure.

RESULTS

Totally 224 patients were diagnosed to have ALL, of them 38 patients went home without receiving any therapy, i.e., the rate of early protocol compliance failure was 17.1%. Of the remaining 186 patients, 22 (10.5%) belonged to interim protocol compliance failure, and 6 cases discontinued the therapy after 15 days treatment, who were classified into late compliance failure. Six cases (10.5%) were regarded as protocol compliance failure among 57 Shanghainese, and so were 22 cases (17.1%) out of 129 non-Shanghainese. There was no significant difference between the two groups (chi(2) = 1.332, P > 0.05). Up to a median 40 months follow-up showed that in 52 patients (31.7%) the treatment failed, of which 37 cases (22.6%) died of incomplete response and relapse, and 15 cases (9.5%) died of therapy complication. Among different risk groups, 24 cases (47.1%) came from high risk group, 18 (34.0%) from medium risk group, and 5 (9.4%) from low risk group. Very significant difference was found among the different risk group (chi(2) = 21.463, P < 0.01). Treatment failure was 28.6% (32/112) in non-Shanghainese and 38.5% (20/52) in Shanghainese. Total failure in protocol compliance and treatment was 42.9% (32 + 22/129) in non-Shanghainese and 45.6% (20 + 6/57) in Shanghainese. The difference of treatment failure was not significant different between the two groups (chi(2) = 1.354, P > 0.05).

CONCLUSION

Protocol compliance failure is the reason as important as the treatment failure for childhood ALL management failure. Either failure should not be neglected. Death from complications was relatively high which needs more attention, especially during induction period. Unusually high death rate occurred in high and medium risk group patients. The grouping criteria may need modification.

摘要

相似文献

1
[Failure of treatment and protocol compliance in patients with acute lymphoblastic leukemia].
Zhonghua Er Ke Za Zhi. 2005 Jul;43(7):490-3.
2
[Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].[采用CCLG - 2008方案治疗儿童标准风险和中度风险急性淋巴细胞白血病的治疗结果]
Zhonghua Er Ke Za Zhi. 2014 Jun;52(6):449-54.
3
[Therapeutic effectiveness of CCLG-97 protocol on standard-risk childhood acute lymphoblastic leukemia].CCLG-97方案对低危儿童急性淋巴细胞白血病的治疗效果
Zhonghua Er Ke Za Zhi. 2005 Jul;43(7):486-9.
4
[Efficacy and prognosis analysis in 188 children with acute lymphoblastic leukemia of China].[188例中国儿童急性淋巴细胞白血病的疗效与预后分析]
Zhonghua Er Ke Za Zhi. 2008 Jul;46(7):498-501.
5
[Clinical study on childhood acute lymphoblastic leukemia diagnosed and treated with 04 Protocol in Chongqing, China].[中国重庆采用04方案诊断和治疗儿童急性淋巴细胞白血病的临床研究]
Zhonghua Er Ke Za Zhi. 2009 Dec;47(12):939-41.
6
The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.土耳其两个中心儿童急性淋巴细胞白血病的长期结果:ALL-BFM 95方案15年的经验
Ann Hematol. 2014 Oct;93(10):1677-84. doi: 10.1007/s00277-014-2106-0. Epub 2014 May 27.
7
[Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].基于SCMC-ALL-2005的儿童急性淋巴细胞白血病多中心试验
Zhonghua Er Ke Za Zhi. 2013 Jul;51(7):495-501.
8
Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.在儿童急性淋巴细胞白血病缓解诱导治疗期间,大剂量甲泼尼龙与传统剂量泼尼松龙相比的长期随访获益情况。
Leukemia. 2003 Feb;17(2):328-33. doi: 10.1038/sj.leu.2402673.
9
[Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].[儿童神经母细胞瘤综合诊疗方案——45例报告]
Zhonghua Er Ke Za Zhi. 2006 Oct;44(10):770-3.
10
[Analysis of therapeutic effectiveness of Nanfang ALL 99 protocol in childhood acute lymphoblastic leukemia patients].南方 ALL 99 方案治疗儿童急性淋巴细胞白血病患者的疗效分析
Zhonghua Er Ke Za Zhi. 2005 Dec;43(12):890-3.